Maraba virus as a potent oncolytic vaccine vector

Area of Science:

• Virology
• Immunology
• Oncology

Background:

• Rhabdovirus Maraba is a potent oncolytic virus.
• Cancer immunotherapy aims to harness the immune system to fight cancer.

Purpose of the Study:

• To engineer an attenuated Maraba strain (MG1) to express a melanoma-associated tumor antigen.
• To evaluate the antitumor immunity and therapeutic efficacy of MG1 in preclinical melanoma models.

Main Methods:

• Engineering of Maraba virus MG1 to express a tumor antigen.
• Assessment of adaptive immunity in tumor-free and tumor-bearing mice.
• Evaluation of an oncolytic prime-boost vaccination protocol in syngeneic murine melanoma models.

Main Results:

• The MG1 vaccine alone did not induce detectable adaptive immunity against the tumor antigen.
• A heterologous prime-boost regimen using MG1 rapidly generated strong antigen-specific T-cell responses.
• The oncolytic prime-boost vaccination protocol significantly extended median survival and achieved complete remission in over 20% of treated mice.

Conclusions:

• Maraba virus MG1 is a potent vaccine vector for cancer immunotherapy.
• MG1 displays both oncolytic activity and the ability to boost adaptive antitumor immunity.
• The oncolytic prime-boost strategy with Maraba MG1 shows significant therapeutic potential for melanoma.